Skip to main content
Caplight Logo









Sigrid Therapeutics

Sigrid Therapeutics

Private
SundbybergHealthcare & Life Scienceshttps://www.sigridthx.com/

Last Round

VC Round

Jan 7, 2026

Est. Valuation

$65.88M

Total Funding Raised

$8.4M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Sigrid Therapeutics is a biotechnology company that develops non-pharmaceutical therapies for metabolic diseases using its proprietary SiPore® technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials

Business Model

B2C

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

medical devicemetabolic healthmesoporous silicaweight managementtype 2 diabetesbiotechnologynon-systemic treatmentdietary supplementgut healthobesity treatmentclinical trialmedical foodweight loss pillcarb blockerbiohacking

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sigrid Therapeutics Comparables

Compare Sigrid Therapeutics with similar companies based on industry and business-model similarity.

Sigrid Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Gelesis Holdings Inc.
76%
AltrixBio Inc.
76%
Allurion
67%

Sigrid Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 7, 2026
VC RoundOct 31, 2023
VC RoundJan 16, 2023
Series ANov 10, 2021
VC RoundSep 5, 2019
Grant
May 28, 2019

Key People

Founding team and executive leadership

Claus Kjaersgaard

Chief Executive Officer

Executive Team

Sana Alajmovic

Co-Founder CEO

Founding Team

Eric Johnston

Chief Operating Officer

Executive Team

Sigrid Therapeutics Investors

Notable investors and investment history

Sigrid Therapeutics investors
InvestorRounds
Axilium CapitalVC Round
Almi Invest ABGrant
Joyance PartnersSeries A, VC Round
Irrus InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 15, 2026

    Grew 68% QoQ, from 19 to 32 employees.

  • May 17, 2026

    Grew 53% QoQ, from 17 to 26 employees.

Sigrid Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sigrid Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sigrid Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSundbyberg
Employee Range32
Year Founded2014
Last FundingJan 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?